Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jun 26:12:1644576.
doi: 10.3389/fcvm.2025.1644576. eCollection 2025.

Editorial: Targeting the interleukin-1β/interleukin-6/C-reactive protein pathway in clinical medicine - a road map to clinical trial design

Jan Torzewski  1 , Ahmed Sheriff  2 , Janos G Filep  3 , Karlheinz Peter  4 , Paul M Ridker  5
Affiliations
Editorial

Editorial: Targeting the interleukin-1β/interleukin-6/C-reactive protein pathway in clinical medicine - a road map to clinical trial design

Jan Torzewski et al. Front Cardiovasc Med. .
No abstract available

Keywords: C-reactive protein; cardiovascular disease; clinical trial; interleukin-1ß (IL-1ß); interleukin-6 (IL-6).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Comment on

  • Editorial on the Research Topic Targeting the interleukin-1β/interleukin-6/C-reactive protein pathway in clinical medicine - a road map to clinical trial design

References

    1. Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Review. Circ Res. (2021) 128(11):1728–46. 10.1161/CIRCRESAHA.121.319077 - DOI - PubMed
    1. Dimosiari A, Patoulias D, Kitas GD, Dimitroulas T. Do interleukin-1 and interleukin-6 antagonists hold any place in the treatment of atherosclerotic cardiovascular disease and related co-morbidities? An overview of available clinical evidence. J Clin Med. (2023) 12(4):1302. 10.3390/jcm12041302 - DOI - PMC - PubMed
    1. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. (2017) 377(12):1119–31. 10.1056/NEJMoa1707914 - DOI - PubMed
    1. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1 beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. (2017) 390(10105):1833–42. 10.1016/S0140-6736(17)32247-X - DOI - PubMed
    1. Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. (2021) 397(10289):2060–9. 10.1016/S0140-6736(21)00520-1 - DOI - PubMed

Publication types

LinkOut - more resources